Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04962295
Other study ID # M2021248
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 1, 2020
Est. completion date December 31, 2026

Study information

Verified date June 2021
Source Peking University Third Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to build a national image-based comprehensive evaluation platform of CSVD through longitudinal collection of imaging based medical data of patients with cerebral small vessel diseases (CSVD). On this basis, the new classification and diagnostic criteria of CSVD are proposed, and the risk prediction model of CSVD is established. By evaluating the prognostic factors of CSVD, early identification of high-risk CSVD population.


Description:

The purpose of this study is to build a national image-based CSVD comprehensive evaluation platform by collecting the medical data of patients with cerebral small vessel diseases (CSVD) based on imaging longitudinally, and to evaluate the risk factors of each type of CSVD, as well as imaging signs, cognition, gait, autonomic nervous system and hemodynamics, sleep, sleep, and so on The outcome of emotion and fundus. In the fields of imaging, molecular and neurocognitive function, we explored the etiology and pathophysiological mechanism of CSVD, proposed new classification and diagnostic criteria of CSVD, and established the risk prediction model of CSVD. By evaluating the prognostic factors of CSVD, early identification of high-risk CSVD population, in order to reduce the burden of CSVD in China in the future.


Recruitment information / eligibility

Status Recruiting
Enrollment 10000
Est. completion date December 31, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years old 2. SVD lesions can be seen on MRI of the head - White matter hyperintensity, Fazekas score = 2 - Fazekas=1 has more than 2 vascular risk factors (hypertension, hyperlipidemia, diabetes, obesity, smoking, and other vascular events except stroke). - Fazekas = 1 and combined with lacunar focus - Imaging findings suggest new subcortical lacunar infarction 3. Daily life independence (MRS = 2) 4. Sign informed consent Note: the imaging definition of small vessel disease refers to the strong guideline 1. The total score of Fazekas was 6, which was the sum of Fazekas scores of subcortical and periventricular white matter lesions. 2. New subcortical lacunar infarction: head MRI examination, subcortical, basal ganglia or brain stem DWI showed high signal (ADC diffusion limited) lesions with diameter < 20 mm, with or without corresponding clinical symptoms; There were new clinical symptoms. FLAIR sequence of head MRI showed flair hyperintense lesions (diameter < 20 mm) in subcortical, basal ganglia or pons. Exclusion Criteria: 1. In acute cerebral infarction, the lesions showed high signal intensity on DWI, and the diameter was more than 20 mm 2. Acute cerebral hemorrhage 3. Acute subarachnoid hemorrhage, or previous history of cerebrovascular malformation or aneurysmal subarachnoid hemorrhage, Or untreated aneurysms (> 3mm in diameter) were found 4. Neurodegenerative diseases, such as AD and PD, have been diagnosed 5. There are clear non angiogenic white matter lesions, such as multiple sclerosis, adult white matter dysplasia, metabolic encephalopathy Diseases, etc 6. Mental disorders diagnosed according to DSM-V diagnostic criteria 7. Contraindications of MRI examination (such as claustrophobia) 8. With severe organic diseases, such as malignant tumor, the expected survival time is less than 5 years 9. Due to geographical or other reasons can not cooperate to complete the follow-up 10. Patients also participated in other clinical trials

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No intervention
No intervention

Locations

Country Name City State
China Peking University Third Hospital Beijing

Sponsors (2)

Lead Sponsor Collaborator
Peking University Third Hospital Beijing Tiantan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The number of patients with each diagnosis. Detailed diagnosis of the patient's disease. At discharge, usually within two weeks.
Secondary mRS score mRS score of patients during 5 years after diagnosis
Secondary New adverse vascular events New adverse vascular events during 5 years after diagnosis
See also
  Status Clinical Trial Phase
Recruiting NCT04041349 - Clinical Observation for the Therapeutic Effect of mNGF on Cognitive Decline in Cerebral Small Vessel Disease Phase 4
Recruiting NCT04109963 - Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment Phase 2
Not yet recruiting NCT06416371 - Retinal Vessel Leakage in Cerebral Small Vessel Disease
Not yet recruiting NCT05967728 - Testing of a System for Remote Ischemic Conditioning in Cerebral Small Vessel Disease and Pre-hospital Stroke Care Phase 2
Completed NCT05714813 - Circuit Training and Retina N/A
Not yet recruiting NCT06077305 - A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke
Not yet recruiting NCT06061692 - Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study(TOPS-CSVD) Phase 4
Completed NCT02801032 - Effect of Tadalafil on Cerebral Large Arteries in Stroke Phase 2
Not yet recruiting NCT05594966 - Neuroimaging Combining Biomarkers for Identifying Long-term Cognitive Dysfunction and Delirium
Terminated NCT02890888 - Effect of Hyperbaric Oxygen on Functional Connectivity in Patients With Cerebral Small Vessel Disease N/A
Recruiting NCT04318119 - Cerebral Small Vessel Disease Registry Study
Recruiting NCT03906123 - The Efficacy of DL-NBP in Patients With Mild Subcortical Ischemic Vascular Dementia N/A
Recruiting NCT05306834 - Stopping Cognitive Decline and Dementia by Fighting Covert Cerebral Small Vessel Disease N/A
Not yet recruiting NCT05583266 - Efficacy of Pentoxifylline on Cerebrovascular Function in Patients With Cerebral Small Vessel Disease(PERFORM) Phase 4
Recruiting NCT05173896 - Improving Cerebral Blood Flow and Cognition in Patients With Cerebral Small Vessel Disease. The ETLAS-2 Trial Phase 2
Recruiting NCT01688505 - Visit-to-Visit Variability in Blood Pressure as a Predictor of Poor Cognitive Function N/A
Recruiting NCT01819441 - Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients Phase 4
Recruiting NCT04330222 - Cambridge 7 Tesla Cerebral Small Vessel Disease Study
Recruiting NCT04298866 - White Matter Hyperintensities Subtypes in Cerebral Small Vessel Disease : 7 Tesla Ultra-high Resolution Imaging MRI N/A
Not yet recruiting NCT06319495 - Stellate Ganglion Block in Patients With Cerebral Small Vessel Disease N/A